Company intelligence / Profile preview

New Garden Pharma

Skopje, North Macedonianewgardengroup.com ↗

Ownership: Private
Development stage: Commercial

Overview

New Garden Pharma operates a state-of-the-art EU-GMP certified facility specializing in the extraction, processing, formulation, packaging, and distribution of pharmaceutical-grade cannabinoid active pharmaceutical ingredients (APIs) and finished dosage forms. The company supplies premium medical cannabis extracts—including oils, tinctures, vapes, flowers—and offers custom formulations as well as contract development and manufacturing services to licensed pharmaceutical partners across Europe. It has recently been acquired by Laso-Bio SA to strengthen their European market presence.

Therapeutic areas: Neurology
Modalities: Small molecule (cannabinoids, THC, CBD)Plant extract (cannabis-derived APIs and FDFs)
Industry: Biotech

Partnerships

Serves licensed pharmaceutical companies as a CDMO partner

Beyond the preview

Go deeper on New Garden Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Garden Pharma.

Explore the full profile